OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
October 24, 2016
Catalent invests $34 million to add a 2 x 2000-L single-use bioreactor system and laboratory space in Madison, WI.
October 02, 2016
This key bioprocessing segment is expecting continued growth
September 21, 2016
The company announced that an August 2016 FDA inspection of the company’s facility resulted in no form 483s.
September 12, 2016
Saneca Pharma is making significant investment in its API capabilities to support client demand for smaller batch sizes and streamlined scale-up.
September 02, 2016
The strategies of a innovation-driven CMO may be different than a capacity-driven CMO.
September 01, 2016
Innovative technologies and services meet needs for existing and emerging biologic-based therapies.
The new facility is solely dedicated to offer extractables and leachables (E&L) testing services to the pharmaceutical and related industries.
The CordenPharma Chenôve, France manufacturing facility completed an FDA Inspection with no 483s reported.
API and drug product manufacturer changes name to align with parent company.
FDA found no observations during recent inspection of Regis Technologies manufacturing site.